September 5, 2017 / 5:09 AM / 3 months ago

BRIEF-Santhera Pharmaceuticals Holding H1 net loss widens to CHF 22.7 million

Sept 5 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG :

* ‍1H 2017 SALES OF CHF 10.9 MILLION, INCREASE OF 51% COMPARED TO 1H 2016​

* H1 ‍NET SALES OF RAXONE AMOUNTED TO CHF 10.9 MILLION (1H 2016: CHF 7.2 MILLION)​

* ‍OPERATING EXPENSES IN FIRST HALF-YEAR WERE CHF 30.5 MILLION (1H 2016: CHF 22.6 MILLION)​

* H1 ‍DEVELOPMENT EXPENSES OF CHF 11.7 MILLION (1H 2016: CHF 8.1 MILLION)​

* ‍OPERATING LOSS IN FIRST HALF OF THIS YEAR AMOUNTED TO CHF 21.4 MILLION (1H 2016: CHF -17.2 MILLION)

* H1 ‍NET RESULT OF CHF -22.7 MLN (1H 2016: CHF -18.0 MLN)

* ‍REITERATES ITS REVENUE OUTLOOK AND CURRENTLY EXPECTS NET SALES OF RAXONE FOR FULL YEAR 2017 TO REACH CHF 21 TO 23 MLN​​​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below